Regulation & law · 27/11/2013
National Institutes of Health to Grant Exclusive Patent License for Cancer and Neurological Disorder Treatments
The National Institutes of Health is considering granting an exclusive patent license to Medicenna Therapeutics, Inc. for the use of GMCSF-BclxL-derived chimeric therapeutics in treating various conditions, including cancer, neutropenia, CNS injury, and Parkinson's disease.